MicroCyto Raises Several Hundred Million RMB in New Equity Financing, with CEC Capital Serving as Exclusive Financial Advisor

Recently, MicroCyto announced the closing of a new round of equity financing worth nearly 300 million RMB. The investors include Beijing New Materials Industry Investment Fund, Beijing Medical and Health Industry Investment Fund, Zhongguancun Capital, and CCB Principal Investment. Prior to this round, MicroCyto has completed the R&D and industrialization of a variety of products targeting human nutrition and animal nutrition. The proceeds from this financing will accelerate the company’s R&D of methanol-based bio-manufacturing pipelines for bulk bio-based products.

CEC Capital acted as the exclusive financial advisor to MicroCyto for this transaction.

At present, MicroCyto has successfully developed multiple strains with high methanol assimilation efficiency, and is accelerating the deployment of methanol-based bio-manufacturing pipelines for bulk bio-based products, including bulk amino acids and bio-based material monomers. This breakthrough not only addresses the raw material constraints plaguing the bio-manufacturing industry, but also helps absorb the excess domestic methanol production capacity. Meanwhile, the production of bulk amino acids using methanol can alleviate China’s long-term reliance on imported soybean meal, consolidate the defense line for food security, and provide a brand-new technical pathway and solution for the bio-manufacturing sector.